About Blue Earth Diagnostics
Blue Earth Diagnostics is a company based in Oxford (United Kingdom) founded in 2014 was acquired by Bracco Imaging in June 2019. Blue Earth Diagnostics has raised $49.42 million across 2 funding rounds from investors including Syncona and Bracco Imaging. The company has 38 employees as of December 31, 2021. Blue Earth Diagnostics has completed 1 acquisition, including Bracco Imaging. Blue Earth Diagnostics offers products and services including PET Radiopharmaceuticals, Axumin, and Posluma. Blue Earth Diagnostics operates in a competitive market with competitors including Guardant Health, Denali Therapeutics, Foundation Medicine, ArcherDX and MiRagen, among others.
- Headquarter Oxford, United Kingdom
- Employees 38 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Blue Earth Diagnostics Limited
- Date of Incorporation 13 Nov, 2013
- Jurisdiction OXFORD, UNITED KINGDOM
-
Annual Revenue
$311.88 (USD)-100as on Dec 31, 2017
-
Net Profit
-$1.75 K (USD)35as on Dec 31, 2017
-
EBITDA
Not available
-
Total Equity Funding
$49.42 M (USD)
in 2 rounds
-
Latest Funding Round
$28.07 M (USD), Series B
Jul 23, 2015
-
Investors
Syncona
& 1 more
-
Employee Count
38
as on Dec 31, 2021
- Investments & Acquisitions
-
Acquired by
Bracco Imaging
(Jun 27, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Blue Earth Diagnostics
Blue Earth Diagnostics offers a comprehensive portfolio of products and services, including PET Radiopharmaceuticals, Axumin, and Posluma.
Radiopharmaceuticals for PET imaging in cancer detection
Agent for prostate cancer imaging via PET scans
Agent for prostate-specific membrane antigen imaging
Funding Insights of Blue Earth Diagnostics
Blue Earth Diagnostics has successfully raised a total of $49.42M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $28.07 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Blue Earth Diagnostics
Blue Earth Diagnostics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Syncona and Bracco Imaging.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are managed via private equity by Syncona.
|
Locked | Locked | Locked | |
|
A portfolio of medical imaging devices for diagnostics is provided.
|
Locked | Locked | Locked |
Investor details for Blue Earth Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Blue Earth Diagnostics
Blue Earth Diagnostics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Bracco Imaging.
Investment portfolio details for Blue Earth Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
A portfolio of medical imaging devices for diagnostics is provided.
|
Locked | Locked | 2004 | Locked |
Complete acquisition details for Blue Earth Diagnostics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Blue Earth Diagnostics
Detailed financials for Blue Earth Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Blue Earth Diagnostics Comparisons
Peer comparison for Blue Earth Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Blue Earth Diagnostics
Blue Earth Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Denali Therapeutics, Foundation Medicine, ArcherDX and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
Detailed competitors of Blue Earth Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Blue Earth Diagnostics
Complete news archive for Blue Earth Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Blue Earth Diagnostics
Blue Earth Diagnostics was founded in 2014.
Blue Earth Diagnostics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Blue Earth Diagnostics is a funded company, having raised a total of $49.42M across 2 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Blue Earth Diagnostics is 38.
Annual revenue of Blue Earth Diagnostics is $311.88 as on Dec 31, 2017.
Founded in 2014 and based in Oxford, United Kingdom, radioactive molecular imaging agents for cancer detection and therapy are developed by the company. Operations center on synthetic amino acid derivatives and PSMA-targeted compounds used in PET imaging. Fluciclovine (18F) is employed for prostate cancer and brain metastases visualization, while rhPSMA-7.c supports PET scanning for prostate cancer, and rhPSMA facilitates radiopharmaceutical therapy in the same area.
Blue Earth Diagnostics's top competitors include Guardant Health, Strand Life Sciences and Juno Therapeutics.
Blue Earth Diagnostics offers PET Radiopharmaceuticals, Axumin, and Posluma.
Blue Earth Diagnostics has made 1 acquisition, including Bracco Imaging.
Blue Earth Diagnostics has 2 investors. Key investors include Syncona, and Bracco Imaging.